Business Context and Reporting Period
Company: uniQure N.V. (Nasdaq: QURE)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: uniQure is a gene therapy company focused on rare and devastating diseases. Its lead candidate, AMT-130, targets Huntington's disease. Other candidates include AMT-260 (epilepsy) and AMT-191 (Fabry disease). The company generates revenue primarily through royalties from the sale of HEMGENIX® to CSL Behring.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 | Q2 2025 | 6M 2026 | 6M 2025 |
|---|---|---|---|---|
| Total Revenues | $5,841 | $5,262 | $9,403 | $6,829 |
| Net Loss | $(81,059) | $(37,719) | $(134,594) | $(81,356) |
| Loss Per Share (Basic/Diluted) | $(1.22) | $(0.69) | $(2.09) | $(1.49) |
| Cash & Cash Equivalents | $413,027 | $80,240 | $413,027 | $253,778 |
| Total Liquidity (Cash + Investments) | $810,335 | $622,541 | $810,335 | $N/A |
| Long-Term Debt (Hercules) | $50,147 | $49,699 | $50,147 | $N/A |
| Royalty Financing Liability | $489,333 | $473,199 | $489,333 | $N/A |
Note: Liquidity includes Cash, Cash Equivalents, and Current Investment Securities.
Material Changes vs. Prior Period
- Revenue Growth: License revenues increased 11% in Q2 2026 ($5.8M) and 38% in the six-month period ($9.4M) compared to 2025, driven by royalty payments from CSL Behring.
- Increased Net Loss: Net loss widened significantly in Q2 2026 ($81.1M vs $37.7M) and 6M 2026 ($134.6M vs $81.4M). This was primarily due to a $16.0M non-cash loss from the fair value adjustment of pre-funded warrants and a $5.9M write-down of an intangible asset related to the termination of the Genezen Commercial Supply Agreement.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses rose 29% in Q2 ($17.4M vs $13.5M) due to increased headcount for commercial preparation. R&D expenses decreased slightly in Q2 ($34.0M vs $35.4M) due to lower manufacturing validation costs for AMT-130.
- Liquidity Position: Cash and investment balances increased substantially to $810.3M as of June 30, 2026, up from $622.5M at year-end 2025, following a $242.7M follow-on public offering in June 2026.
Guidance, Outlook, and Risks
- Regulatory Outlook (AMT-130): Following a Type B meeting in June 2026, the FDA agreed that a Biologics License Application (BLA) under the accelerated approval pathway is reasonable based on existing data. The company expects to submit the BLA in Q3 2026. The FDA requires alignment on a confirmatory study design prior to submission.
- UK Submission: A successful pre-submission meeting with the UK MHRA was held in March 2026; submission is planned for Q3 2026.
- Clinical Updates:
- AMT-260 (Epilepsy): Preliminary data showed meaningful seizure reductions in 3 of 6 patients in the low-dose cohort.
- AMT-191 (Fabry): Dose-dependent enzyme activity elevations observed; dosing paused in mid/high cohorts pending evaluation of liver enzyme elevations.
- Capital Resources: Management believes current resources ($810M+ liquidity) are sufficient to fund operations into 2030, including commercial launch and confirmatory studies for AMT-130.
- Legal Proceedings: A class action lawsuit (Scocco v. uniQure) was filed in February 2026 regarding statements about AMT-130 data and BLA timing. An amended complaint was filed in July 2026. The company intends to vigorously defend the claims and has not recorded a liability.
- Debt Amendment: In July 2026, the company amended its Hercules loan facility, extending the draw period for the $100M tranche to September 30, 2027.
Investor Verification Checklist
- BLA Submission Timeline: Verify the Q3 2026 BLA submission date and the specific design of the required confirmatory study agreed upon with the FDA.
- AMT-191 Safety: Monitor the resolution of liver enzyme elevations in the AMT-191 trial and the resumption of dosing in mid/high cohorts.
- Legal Exposure: Track the progress of the Scocco class action lawsuit and any potential settlement or dismissal outcomes.
- Pre-Funded Warrants: Assess the impact of the fair value liability ($24.2M) on future earnings, as this is a non-cash item sensitive to stock price volatility.
- Royalty Financing: Review the effective interest rate (10.0% - 11.5%) and the impact of the $489M liability on future cash flows from HEMGENIX royalties.